Dupont Nutrition Biosciences Aps

International N&h Denmark Aps

Sampo Lahtinen

Rodolphe Barrangou

Arthur Ouwehand

Nina Rautonen

Kirsti Tiihonen

Sofia Forssten

Heli Putaala

Pierre Desreumaux

Didier Carcano

Harri Mäkivuokko

Jaana Mättö

John Konhilas

Björn Andersch

Markus Lehtinen

Rémy Burcelin

Lotta Stenman

Ronald B Turner

Inger Mattsby-Baltzer

Janne Nikkilä

David Pyne

Allan Cripps

Nicholas West

The present invention relates to bacteria and metabolites thereof that are capable of binding to vaginal cells and producing hydrogen peroxide, their use in probiotic compositions and food products and methods for their selection. The invention also relates to the use of said bacteria, metabolites and probiotic compositions for the prevention and/or treatment of urogenital disorders.

Bacteria

The present invention relates to bacteria and metabolites thereof that are capable of binding to A, B and/or O blood type antigens or which are acid and/or bile tolerant, their use in probiotic compositions and food products, and methods for their selection. The invention also relates to the use of said bacteria and metabolites for the prevention and/or treatment of gastrointestinal disorders.

The present invention relates to composition derivable from a bifidobacteria, methods and uses thereof, for use in modulating the immune system in a subject by affecting viral action and/or viral effects in said subject. Furthermore, said composition may also be used in reducing the risk of development and exacerbation of chronic respiratory diseases such as asthma and COPD in a subject; preferably by modulating the immune system in the subject by affecting viral action and/or viral effects in said subject.

Immunomodulatory composition comprising bifidobacteria

The invention relates to use of a bacterium selected from a lactic acid bacterium, aor a mixture of any thereof for treating metabolic endotoxemia, inhibiting bacterial translocation and regulating lipid absorption in a mammal.

Lactic acid bacteria andfor treating endotoxemia

This invention relates to new uses of(particularly, although not exclusively, probiotic), and to food products, feed products, dietary supplements and pharmaceutical formulations containing them. The bacteria are suitable for the treatment of myocardial infarction, dilated cardiomyopathy, inflammatory heart disease (including endocarditis, inflammatory cardiomegaly and myocarditis), and congestive heart failure.

Bifidobacteria for treating cardiac conditions

Lactic acid bacteria and bifidobacteria for treating endotoxemia

Growing community of inventors

Lohja, Finland

Sampo Lahtinen